Lancet Healthy Longevity最新文献

{"title":"Group schema therapy combined with psychomotor therapy for older adults with a personality disorder: an open-label, multicentre, randomised controlled trial","authors":"Martine S Veenstra-Spruit MSc ,&nbsp;Renske Bouman MSc ,&nbsp;Silvia DM van Dijk PhD ,&nbsp;Antoinette DI van Asselt PhD ,&nbsp;Prof Sebastiaan PJ van Alphen PhD ,&nbsp;Dorothee H Veenstra MSc ,&nbsp;Marije de Ruiter MSc ,&nbsp;Saskia E Troost MD ,&nbsp;Monique W Lammers MD ,&nbsp;Frank Vulker MSc ,&nbsp;Maureen MJ Smeets-Janssen MD ,&nbsp;Rob HS van den Brink PhD ,&nbsp;Prof Richard C Oude Voshaar MD","doi":"10.1016/S2666-7568(24)00001-1","DOIUrl":"https://doi.org/10.1016/S2666-7568(24)00001-1","url":null,"abstract":"<div><h3>Background</h3><p>Although several types of psychotherapy effectively reduce psychological distress associated with personality disorders, randomised controlled trials (RCT) have systematically excluded older patients. We aimed to examine the effectiveness of group schema therapy combined with psychomotor therapy (GST + PMT) in later life compared with treatment as usual (TAU).</p></div><div><h3>Methods</h3><p>We did an open-label, multicentre, RCT in eight outpatient clinics for geriatric psychiatry in the Netherlands. Adults aged 60 years or older with a full or subthreshold cluster B or C personality disorder according to DSM criteria were included and randomly assigned 1:1 to GST + PMT or TAU by an independent researcher applying a computer-generated sequence per study site when 8 to 16 patients had given informed consent; investigators and interviewers were kept blinded until end of follow-up. Included individuals received 20 weekly sessions of GST + PMT or TAU with 1 year of follow-up. The primary outcome was psychological distress, measured with the 53-item Brief Symptom Inventory. The trial was registered with International Clinical Trials Registry Platform, NTR6621.</p></div><div><h3>Findings</h3><p>Of the 145 study participants recruited between Feb 21, 2018, and Jan 21, 2020, 102 patients (median age of 69 years [IQR 63–71], 62 [61%] female) who concluded therapy before the COVID-19 pandemic (cutoff March 20, 2020) were included in the intention-to-treat analysis (51 in each study group), because COVID-19 measures substantially disrupted delivery of group therapy. GST + PMT significantly improved psychological distress compared with TAU over the 6-month treatment period (Cohen's <em>d</em> 0·42, 95% CI 0·16 to 0·68; p=0·0016). The pre-post effect of GST + PMT remained stable during follow-up, whereas patients receiving TAU further improved, resulting in a non-significant difference between groups at 1 year (Cohen's <em>d</em> 0·21, 95% CI –0·07 to 0·48; p=0·14). No patients reported adverse events.</p></div><div><h3>Interpretation</h3><p>Psychotherapy focused on personality disorders is effective in later life, resulting in a faster improvement in psychopathology than TAU. Future studies should focus on increasing effectiveness by intensifying or prolonging treatment.</p></div><div><h3>Funding</h3><p>Netherlands Organization for Health Research and Development.</p></div><div><h3>Translation</h3><p>For the Dutch translation of the abstract see Supplementary Materials section.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000011/pdfft?md5=3f188184674d7d5927e0a8759dab8fc8&pid=1-s2.0-S2666756824000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging modifiable risk factors and cognitive decline: the mediating role of brain age","authors":"Marcella Montagnese ,&nbsp;Timothy Rittman","doi":"10.1016/S2666-7568(24)00042-4","DOIUrl":"https://doi.org/10.1016/S2666-7568(24)00042-4","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000424/pdfft?md5=4eea5e01095545201a7baa81af014954&pid=1-s2.0-S2666756824000424-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social connection and end-of-life outcomes among older people in 19 countries: a population-based longitudinal study","authors":"Prof Lara Pivodic PhD ,&nbsp;Prof Lieve Van den Block PhD ,&nbsp;Fedja Pivodic MSc","doi":"10.1016/S2666-7568(24)00011-4","DOIUrl":"10.1016/S2666-7568(24)00011-4","url":null,"abstract":"<div><h3>Background</h3><p>Social connection is a key determinant of health, but its role in shaping end-of-life outcomes is poorly understood. We examined changes in structure, function, and quality components of social connection in older people's last years of life, and the extent to which social connection predicts end-of-life outcomes (ie, symptoms, health-care utilisation, and place of death).</p></div><div><h3>Methods</h3><p>This study used longitudinal data of representative samples from across 18 European countries and Israel in the Survey of Health, Ageing, and Retirement in Europe (SHARE), the largest European cohort study of people aged 50 years or older. We included deceased participants of waves 4 and 6 (which contained social network modules) for whom a proxy provided an end-of-life interview. We did paired sample <em>t</em>-tests (for continuous variables), Wilcoxon signed-rank tests (for ordinal variables), and McNemar's tests (for non-ordinal categorical variables) to assess changes in structure, function, and quality components of social connection between waves 4 and 6. To examine social connection as a predictor of end-of-life outcomes, we used social connection data from wave 6 core interviews and end-of-life interviews from wave 7, conducted with a proxy respondent covering the deceased participant's last year of life. End-of-life outcomes included symptoms (pain, breathlessness, and anxiety or sadness) in the last month of life, health-care utilisation in the last year of life, and place of death. We conducted a mixed-effects logistic regression analysis per social connection measure, for each end-of-life outcome.</p></div><div><h3>Findings</h3><p>Data were collected in 2011–12 for wave 4, 2015–16 for wave 6, and 2017–18 for wave 7. We studied 3356 individuals (mean age at death was 79·7 years [SD 10·2]), with interviews conducted, on average, 4·6 (1·2) years (wave 4) and 1·1 (0·7) years (wave 6) before death. From wave 4 to wave 6, the following changes in social connection were observed: proportion of married or partnered participants (from 1406 [60·9%] of 2310 to 1438 [57·1%] of 2518; p&lt;0·0001), receiving personal care or practical help (from 781 [37·2%] of 2099 to 1334 [53·1%] of 2512; p&lt;0·0001), loneliness (from mean 1·4 [SD 0·5] to 1·5 [0·6]; p&lt;0·0001; scale 1–3), satisfaction with social network (from 8·8 [1·67] to 8·7 [1·7]; p=0·037; scale 0–10), and emotional closeness to social network (eg, from 1883 [88·8%] of 2121 to 1710 [91·3%] of 1872 participants who indicated being either very close or extremely close to social network members; p&lt;0·0001). Higher levels of loneliness at wave 6 predicted a greater likelihood of experiencing symptoms in the last month of life (odds ratio range across symptoms: 1·29 [95% CI 1·08–1·55] to 1·58 [1·32–1·89]). Being married (1·32 [1·03–1·68]) or receiving personal care or practical help (1·25 [1·04–1·49]) predicted death in hospital.</p></div><div><h3>Interpretation</h","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000114/pdfft?md5=bd00b9848ee49e7aabb3a1b77c13426f&pid=1-s2.0-S2666756824000114-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global crisis of loneliness: a call for contextualised, mechanistic research","authors":"Hannah M O'Rourke","doi":"10.1016/S2666-7568(24)00030-8","DOIUrl":"10.1016/S2666-7568(24)00030-8","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000308/pdfft?md5=2feaec3240af9681c9224768ca8f9ce0&pid=1-s2.0-S2666756824000308-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involuntary closures of for-profit care homes in England by the Care Quality Commission","authors":"Anders Bach-Mortensen PhD ,&nbsp;Benjamin Goodair MSc ,&nbsp;Michelle Degli Esposti PhD","doi":"10.1016/S2666-7568(24)00008-4","DOIUrl":"10.1016/S2666-7568(24)00008-4","url":null,"abstract":"<div><p>Adult social care services in England are struggling, and sometimes failing, to supply the quality of care deserved by the most vulnerable people in society. The Care Quality Commission (CQC) is responsible for protecting the recipients of this crucial public service. Their strongest enforcement is the ability to cancel the registration—the legal right to operate—of a health or social care provider. Using novel data from the CQC, we show that the proportion of care home closures due to CQC enforcements, relative to all closures, is increasing. Since 2011, 816 care homes (representing 19 918 registered beds) have been involuntarily closed by the CQC. Our results show that effectively all involuntary closures (804/816) occurred in for-profit care homes. This data emphasises the need for a comprehensive assessment of the impact of for-profit provision on the quality and sustainability of adult social care in England.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000084/pdfft?md5=a9aa35d516035b1845f62591e51e415c&pid=1-s2.0-S2666756824000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review","authors":"Kathryn Nicholson PhD ,&nbsp;Winnie Liu BSc ,&nbsp;Daire Fitzpatrick MD ,&nbsp;Kate Anne Hardacre BMSc ,&nbsp;Sarah Roberts MD ,&nbsp;Jennifer Salerno PhD ,&nbsp;Prof Saverio Stranges MD PhD ,&nbsp;Martin Fortin MD MSc ,&nbsp;Prof Dee Mangin MBCHB DPH","doi":"10.1016/S2666-7568(24)00007-2","DOIUrl":"10.1016/S2666-7568(24)00007-2","url":null,"abstract":"<div><p>Multimorbidity (multiple conditions) and polypharmacy (multiple medications) are increasingly common, yet there is a need to better understand the prevalence of co-occurrence. In this systematic review, we examined the prevalence of multimorbidity and polypharmacy among adults (≥18 years) and older adults (≥65 years) in clinical and community settings. Six electronic databases were searched, and 87 studies were retained after two levels of screening. Most studies focused on adults 65 years and older and were done in population-based community settings. Although the operational definitions of multimorbidity and polypharmacy varied across studies, consistent cut-points (two or more conditions and five or more medications) were used across most studies. In older adult samples, the prevalence of multimorbidity ranged from 4·8% to 93·1%, while the prevalence of polypharmacy ranged from 2·6% to 86·6%. High heterogeneity between studies indicates the need for more consistent reporting of specific lists of conditions and medications used in operational definitions.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000072/pdfft?md5=8a7dd41890037b965e15a057ab456b6c&pid=1-s2.0-S2666756824000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-life cumulative exposure to excess bodyweight and midlife cognitive function: longitudinal analysis in three British birth cohorts","authors":"Scott T Chiesa PhD ,&nbsp;Tom Norris PhD ,&nbsp;Victoria Garfield PhD ,&nbsp;Prof Marcus Richards PhD ,&nbsp;Prof Alun D Hughes PhD","doi":"10.1016/S2666-7568(24)00005-9","DOIUrl":"https://doi.org/10.1016/S2666-7568(24)00005-9","url":null,"abstract":"<div><h3>Background</h3><p>Excess bodyweight (BMI &gt;25 kg/m²) in midlife (age 40–65 years) has been linked to future cognitive decline and an increased risk of dementia. Whether chronic exposure to excess bodyweight in the early decades of life (&lt;40 years) is associated with compromised cognitive function by midlife, however, remains unclear. This study therefore aimed to test potential bidirectional direct and indirect pathways linking cumulative exposure to excess bodyweight and cognitive function in the early decades of life.</p></div><div><h3>Methods</h3><p>In this longitudinal analysis, harmonised measures of BMI and cognitive function were available in 19 742 participants aged 47–53 years recruited to the 1946 National Survey of Health and Development (n=2131), the 1958 National Child Development Study (n=9385), and the 1970 British Cohort Study (n=8226). Individual BMI trajectories spanning three decades from age 10–40 years were created for each participant and excess bodyweight duration, BMI change between ages, and cumulative excess bodyweight exposure were calculated. Harmonised measures of verbal and non-verbal ability, mathematical ability, and reading ability were used to create a latent factor for childhood cognitive function, and immediate and delayed recall, animal naming, and letter-search speed tests were used for midlife cognitive function. Multivariable linear regression and structural equation models (SEM) were used to test for potential bidirectional relationships between cognition and excess bodyweight in both individual cohorts and pooled datasets while accounting for other potential early-life confounders.</p></div><div><h3>Findings</h3><p>Increases in BMI during adolescence and greater cumulative exposure to excess bodyweight across early life were associated with lower midlife cognitive function in all cohorts (eg, pooled difference in cognitive function per 10 years excess bodyweight duration –0·10; 95% CI –0·12 to –0·08; p&lt;0·001). Further adjustment for childhood cognitive function attenuated many of these associations towards the null (eg, pooled difference in cognitive function per 10 years excess bodyweight duration –0·04; 95% CI –0·06 to –0·02; p=0·001), however, with any remaining associations then fully attenuating once further adjusted for other early-life factors (eg, pooled difference in cognitive function per 10 years excess bodyweight duration 0, –0·03 to 0·01; p=0·38). In the reverse direction, low childhood cognition was associated with greater cumulative exposure to excess bodyweight over the next four decades, although much of this relationship was found to probably be explained via other potentially modifiable upstream early-life factors such as childhood disadvantage. SEM in all cohorts suggested the presence of modest direct and indirect pathways connecting earlier cognitive function to later excess bodyweight, but scarce evidence for an effect of early-life excess bodyweight on c","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000059/pdfft?md5=58dedd6dbb989655c2147d4b4a88df1b&pid=1-s2.0-S2666756824000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140000021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ATEMPTing to navigate between “lower is better” and “less is more”","authors":"Nicholas M Pajewski ,&nbsp;Jordana B Cohen","doi":"10.1016/S2666-7568(24)00024-2","DOIUrl":"10.1016/S2666-7568(24)00024-2","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000242/pdfft?md5=757b23fdbc3ae9c64f5acc3815320a8b&pid=1-s2.0-S2666756824000242-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is systemic anticancer treatment suitable for older patients?","authors":"Peter Mu-Hsin Chang","doi":"10.1016/S2666-7568(24)00023-0","DOIUrl":"https://doi.org/10.1016/S2666-7568(24)00023-0","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000230/pdfft?md5=56b8c43e07e6cdb7df97c530c64e765a&pid=1-s2.0-S2666756824000230-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial","authors":"Tetsuya Kawahara MD ,&nbsp;Prof Gen Suzuki MD ,&nbsp;Shoichi Mizuno PhD ,&nbsp;Naoki Tominaga MD ,&nbsp;Mikio Toda MD ,&nbsp;Nagahiro Toyama MD ,&nbsp;Prof Tetsuya Inazu MD ,&nbsp;Chie Kawahara MD ,&nbsp;Yosuke Okada MD ,&nbsp;Prof Yoshiya Tanaka MD","doi":"10.1016/S2666-7568(24)00009-6","DOIUrl":"10.1016/S2666-7568(24)00009-6","url":null,"abstract":"<div><h3>Background</h3><p>Observational studies show inverse associations between serum 25-hydroxyvitamin D concentrations and sarcopenia incidence; however, it remains unclear whether treatment with vitamin D prevents its development. We aimed to assess whether treatment with active vitamin D (eldecalcitol [0·75 μg per day]) can reduce the development of sarcopenia among adults with prediabetes.</p></div><div><h3>Methods</h3><p>This randomised, double-blind, placebo-controlled, multicenter trial as an ancillary study was conducted at 32 clinics and hospital sites in Japan. Participants were assigned (1:1) by using a central randomisation method in which a randomisation list was made for each hospital separately using a stratified permuted block procedure. The primary endpoint was sarcopenia incidence during 3 years in the intention-to-treat population defined as weak handgrip strength (&lt;28 kg for men and &lt;18 kg for women) and low appendicular skeletal muscle index (&lt;7·0 kg/m² for men and &lt;5·7 kg/m² for women in bioelectrical impedance analysis). Although the usual criterion of hypercalcaemia was 10·4 mg/dL (2·6 mmol/L) or higher, hypercalcaemia that was enough to discontinue the study was defined as 11·0 mg/dL or higher. This study is registered with the UMIN clinical trials registry, UMIN000005394.</p></div><div><h3>Findings</h3><p>A total of 1094 participants (548 in the eldecalcitol group and 546 in the placebo group; 44·2% [484 of 1094] women; mean age 60·8 [SD 9·2] years) were followed up for a median of 2·9 (IQR 2·8–3·0) years. Eldecalcitol treatment as compared with placebo showed statistically significant preventive effect on sarcopenia incidence (25 [4·6%] of 548 participants in the eldecalcitol group and 48 [8·8%] of 546 participants in the placebo group; hazard ratio 0·51; 95% CI 0·31 to 0·83; p=0·0065). The incidence of adverse events did not differ between the two groups.</p></div><div><h3>Interpretation</h3><p>We found that treatment with eldecalcitol has the potential to prevent the onset of sarcopenia among people with prediabetes via increasing skeletal muscle volume and strength, which might lead to a substantial risk reduction of falls.</p></div><div><h3>Funding</h3><p>Kitakyushu Medical Association.</p></div><div><h3>Translation</h3><p>For the Japanese translation of the abstract see Supplementary Materials section.</p></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666756824000096/pdfft?md5=1097e8a64c8b845163d6a6e0bad59385&pid=1-s2.0-S2666756824000096-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}